Hepatology News and Research RSS Feed - Hepatology News and Research

Hepatology is the branch of medicine that incorporates study of liver, gallbladder, biliary tree and pancreas as well as management of their disorders.
Women with IBD may be at increased risk for developing cervical cancer

Women with IBD may be at increased risk for developing cervical cancer

Women with inflammatory bowel disease (IBD) may be at increased risk of cervical dysplasia and cancer, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center. [More]
HBV genotype C HBeAg seroconversion rate ‘negligible’

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend. [More]
Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates. [More]
Regenstrief researchers create accurate system for tracking quality of colonoscopies

Regenstrief researchers create accurate system for tracking quality of colonoscopies

An accurate system for tracking the quality of colonoscopies and determining the appropriate intervals between these procedures could contribute to both better health outcomes and lower costs. Clinician-researchers from the Regenstrief Institute have created and tested such a system in the nation's first multiple institution colonoscopy quality measurement study utilizing natural language processing and report that it is as accurate but less expensive than human review. [More]
MedUni Vienna experts recommend regular colonoscopy screening to prevent bowel cancer

MedUni Vienna experts recommend regular colonoscopy screening to prevent bowel cancer

Bowel cancer is one of the most common types of cancer. The prognosis depends greatly on the stage at which the tumour is discovered. Colonoscopy is regarded as the best method for identifying pre-cancerous changes. If these changes are treated promptly, the disease can be stopped in its tracks. [More]
Better understanding of stomach's response to infection could lead to therapies against gastric damage

Better understanding of stomach's response to infection could lead to therapies against gastric damage

A better understanding of the stomach's immune response to Helicobater pylori (H. pylori) infection could lead to new therapies targeting damage in the stomach, report researchers in the March issue of Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association. [More]
Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers. [More]
SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France. [More]
AGA receives gift to support young investigators advance into neuroenteric disease research

AGA receives gift to support young investigators advance into neuroenteric disease research

The American Gastroenterological Association Research Foundation has received a generous gift from prominent San Francisco philanthropist Athena Blackburn, which will create new research opportunities for young investigators who are interested in neuroenteric disease. [More]
Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term tenofovir disoproxil fumarate therapy is effective in Chinese patients with chronic hepatitis B virus infection who have relapsed after treatment with multiple nucleos(t)ide analogues, research suggests. [More]
SLU researchers halt fatty liver disease in animal model

SLU researchers halt fatty liver disease in animal model

Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences. [More]
Rutgers patient gets second chance at life following liver transplant

Rutgers patient gets second chance at life following liver transplant

Mati Muñoz is 65 years old - filled with the enthusiastic energy that comes with a second chance at life. A decade ago, says Muñoz, who lives in Woodbridge Township, N.J., her liver was being destroyed by hepatitis C, a viral disease she believes she contracted as a girl in her native Cuba from a poorly sterilized needle used in a medical procedure. [More]
New study shows that chronic narcotic use more prevalent in children with IBD

New study shows that chronic narcotic use more prevalent in children with IBD

Chronic narcotic use is more than twice as prevalent in children with inflammatory bowel disease (IBD), compared with children without this disease, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association. [More]
Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). [More]
New AGA guideline provides guidance to prevent HBV reactivation

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others. [More]
Update: Bariatric surgery can improve obesity-related health problems in children, adolescents

Update: Bariatric surgery can improve obesity-related health problems in children, adolescents

Bariatric surgery--as a last resort when conservative interventions have failed--can improve liver disease and other obesity-related health problems in severely obese children and adolescents, according to a position paper in the Journal of Pediatric Gastroenterology and Nutrition, official journal of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. [More]
Researchers develop new MRI-based technique to better detect NAFLD in children

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children. [More]
Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. [More]
Advertisement
Advertisement